Mylan’s NHK-Fintiv challenge denied by SCOTUS

The US Supreme Court has rejected a bid from generic drugmaker Mylan (now part of Viatris) to overturn the NHK-Fintiv rule.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Mylan gets green light to challenge Neurim melatonin patent

25 January 2022 Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Americas

Mylan gets Fed Circ reprieve in inhaler dispute

9 December 2021 Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

Americas

Mylan scores multiple sclerosis patent win over Biogen

23 June 2020 Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.

More on this story

Big Pharma

Mylan gets green light to challenge Neurim melatonin patent

Americas

Mylan gets Fed Circ reprieve in inhaler dispute

9 December 2021 Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

Americas

Mylan scores multiple sclerosis patent win over Biogen

23 June 2020 Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.

More on this story

Big Pharma

Mylan gets green light to challenge Neurim melatonin patent

Americas

Mylan gets Fed Circ reprieve in inhaler dispute

9 December 2021 Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

Americas

Mylan scores multiple sclerosis patent win over Biogen

23 June 2020 Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.